Evolutionary development in the human populations immune to Plasmodium vivax due to the presence of a mutated enhancer for the glycoprotein present on their red blood corpuscles (RBCs). Introduction: A protist named P. vivax is mainly responsible for causing malaria. It gets attached to the RBCs after entering the blood. It has been found that some human populations in Africa are immune to P. vivax due to the absence of this particular glycoprotein on their RBCs. The transcription of this glycoprotein is influenced by the enhancers in a variety of tissues. In individuals immune to this form of malaria, the enhancer that is normally expressed in RBC precursors is mutated.

Question

Want to see the full answer?

Answer 1

Question

Chapter 19.4, Problem 3R

Summary Introduction

To review:

Evolutionary development in the human populations immune to Plasmodium vivax due to the presence of a mutated enhancer for the glycoprotein present on their red blood corpuscles (RBCs).

Introduction:

A protist named P. vivax is mainly responsible for causing malaria. It gets attached to the RBCs after entering the blood. It has been found that some human populations in Africa are immune to P. vivax due to the absence of this particular glycoprotein on their RBCs. The transcription of this glycoprotein is influenced by the enhancers in a variety of tissues. In individuals immune to this form of malaria, the enhancer that is normally expressed in RBC precursors is mutated.

Expert Solution & Answer

Want to see the full answer?

Check out a sample textbook solution

See solution

Students have asked these similar questions

The MARCH-1 E3-ubiquitin ligase is expressed in B cells, dendritic cells, and macrophages. The pathway regulated by MARCH-1 is targeted by some pathogens in an immune evasion strategy. In this strategy, the pathogens encode: A protein that induces degradation of MARCH-1 A protein that mimics MARCH-1 and functions similarly A protein that binds to MARCH-1 and inhibits its function A protein that is induced by IL-10 in macrophages and dendritic cells A protein that induces degradation of CD86

I just read an abstract of the paper “Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway” and noted that “DDAs and TRAIL synergize to kill cancer cells and are cytotoxic to HER2+ cancer cells with acquired resistance to the EGFR/HER2 tyrosine kinase inhibitor Lapatinib.” For the last sentence, I am not sure the meaning of the “acquired resistance to the EGFR/HER2 tyrosine kinase inhibitor Lapatinib”. Is the “acquired resistance ... to inhibitor” a good thing or bad thing, as far as the synergize effect of DDAs and TRAIL”? Hope that expert can help.

See figure 12.16b regarding the process by which cyclin regulates the Cdk. Suppose that the cyclin binding site in the Cdk contains these FOUR amino acids in this order from top to bottom: serine, lysine, aspartic acid acid and lysine and the Cdk binding site in the cyclin contains these FOUR amino acids in this order from top to bottom: aspartic acid, aspartic acid, lysine and serine. Use the schematics below to show the R groups and how they might interact to create the cyclin.cdk complex. Label both binding sites, show all charges that will be used to create any bonds, and label all bonds formed and add the ATP active site. A Explain what a kinase does and how the cyclin controls the activity of the Cdk.